Target intelligence / Profile preview

Major histocompatibility complex, class II, DP alpha 1 (HLA-DPA1)

Target
HLA-DPA1
Molecular classification
Major histocompatibility complex (MHC) class II protein, Immunoglobulin superfamily, Receptor (immune receptor)
01

Overview

Major histocompatibility complex, class II, DP alpha 1 (HLA-DPA1) is the alpha-chain subunit of the HLA-DP molecule, a heterodimeric MHC class II cell surface receptor expressed on antigen-presenting cells such as B lymphocytes, dendritic cells, and macrophages[1][4][5]. Together with its beta-chain partner (HLA-DPB1), it binds peptides derived from extracellular antigens and presents them to CD4+ T lymphocytes, playing a crucial role in adaptive immune responses and immune regulation[1][2][4]. The gene encoding HLA-DPA1 is highly polymorphic, contributing to the diversity of immune recognition[2]; specific alleles of HLA-DPA1 have been associated with susceptibility to autoimmune conditions, infectious disease outcomes, and transplantation compatibility[2][3]. Because of its central function in antigen presentation, HLA-DPA1 is a critical immunological target in clinical contexts such as transplantation, vaccine response, autoimmunity, and infectious diseases[2][3].

Other names
HLA class II histocompatibility antigen, DP alpha 1 chainDPA1HLA-DP1AHLASBDP(W3)DP(W4)HLA-SB alpha chainMHC class II DP3-alphaMHC class II DPA1HLA-DPAHLADPHLA-DPB1PLT1MHC class II antigen DP alpha chainMHC class II protein
02

Biological functions

Antigen presentation to T cellsRegulation of adaptive immune responsePeptide binding and display on antigen-presenting cells
03

Disease associations

Autoimmune diseases (e.g., rheumatoid arthritis, juvenile idiopathic arthritis, multiple sclerosis)Infection (e.g., hepatitis B susceptibility/persistence)Transplant rejection and compatibilityCancer (mainly via immune surveillance/modulation)
04

Safety considerations

Alloreactivity in transplantation (graft rejection, graft-versus-host disease)Genetic polymorphism may affect therapeutic and vaccine responses
05

Biomarkers

HLA typing for transplant compatibilityPolymorphism/allele variants as risk or prognostic markers in autoimmunity and infectious diseases

Beyond the preview

Go deeper on Major histocompatibility complex, class II, DP alpha 1 (HLA-DPA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Major histocompatibility complex, class II, DP alpha 1 (HLA-DPA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call